AbbVie (NYSE:ABBV) announced Thursday that it will acquire Immunogen (IMGN) and its flagship cancer therapy, Elahere, in a deal worth $31.26 per share. The transaction values ImmunoGen (NASDAQ:IMGN) at a total equity value of approximately $10.1 billion and is expected to close in the middle of 2024. Elahere is considered a "first-in-class antibody-drug...
IMGN had great earnings the last days of April and has been trending up ever since. It is riding the upper Bollinger band consistently in this past wee. The volume spike after earnings has subsided but ongoing volume is at about 5X the moving average of early April and March. Increased volume supports price momentum. The volume spike here is obvious and...
I was scanning stocks for chart patterns and came across Immunogen Inc. (IMGN) with a double-top already formed. IMGN has been trading in a downward channel since February 2021 and shows no sign of stopping yet. The price has reached a major support level of about 4.97, with only one major breach back in May. On three occasions it has dipped below slightly to...
Golden cross MA50 and MA200 as a support Going long
Try to catch the near term momentum. Entry at the current level and adding position on possible pullback. Disclaimer, this is only for entertainment and education purposes and doesn't serve by any means as a buy or sell recommendation. Personally I hold both long term long positions and occasionally short term short position, for disclosure purpose.
$IMGN can be categorized as penny stock because its price per share is below $10 Given this fact this trade idea should be considered risky. But nothing in life that is worthy is free of risk, right? Since this is a volatile stock I would strongly suggest you should have a proper plan to execute it as a skilled surgeon In particular, you should set your Stop...
monitor the volume to determine if it will break the resistance or not.
Hi, Watch out for a reversal breakdown at ~ $5.25. A great opportunity to short sell.
Hi, today we are going to talk about Immunogen and its current landscape. Immunogen is poised to receive increasing attention from the market after the announcement that it will start new trials based on an FDA advice that a new single-arm study in ovarian cancer could support accelerated approval for Mirvetuximab Soravtansine. We must remember that statistics...
My graph shows that the stock has a habit to recover to great performance within a period of approx. 200 days (blue squares). Furthermore I've identified 3 support/resistance lines (black lines). My guess is that the climb will be kept within the margin of the lower yellow field, were you also can we my prediction (blue lines). P.S. Pardon me if I'm not down...
IMGN Daily 34 SMA x 500 Hull MA... the brschultz "moment"
IMGN needs 34 SMA x 500 Hull to “BUY”
Astounding Results - IMGN up 11% after entry/bottom call
IMGN Target is 340 Day SMA or $7.00
Daily Model chooses NOW as time to buy IMGN for long term low
Failed on IMGN first round - OUCH!!! Next entry will be based on 3 hour chart - 34 SMA crossing 500 Hull MA ( guessing it will be early-mid June br
IMGN is my pick for 2019